TABLE 2.
Characteristics of colorectal cancer patients by the status of p53 Mutation based on loss of function classification (N = 247).
| TP53 WT (n = 90) | TP53 Mut (n = 157) | p Value | TP53 likely LOF Mut (n = 98) | TP53 known LOF Mut (n = 59) | p Value | |
|---|---|---|---|---|---|---|
| Sex | 0.247 | 1.000 | ||||
| Male | 51 (56.67%) | 102 (64.97%) | 64 (65.31%) | 38 (64.41%) | ||
| Female | 39 (43.33%) | 55 (35.03%) | 34 (34.69%) | 21 (35.59%) | ||
| Onset | 0.337 | 0.875 | ||||
| Early onset | 27 (30.00%) | 37 (23.57%) | 24 (24.49%) | 13 (22.03%) | ||
| Late onset | 63 (70.00%) | 120 (76.43%) | 74 (75.51%) | 46 (77.97%) | ||
| Sidedness | 0.006 | 1.000 | ||||
| Left‐sided | 60 (66.67%) | 130 (82.80%) | 81 (82.65%) | 49 (83.05%) | ||
| Right‐sided | 30 (33.33%) | 27 (17.20%) | 17 (17.35%) | 10 (16.95%) | ||
| Stage | 0.188 | 1.000 | ||||
| III | 47 (52.22%) | 67 (42.68%) | 42 (42.86%) | 25 (42.37%) | ||
| IV | 43 (47.78%) | 90 (57.32%) | 56 (57.14%) | 34 (57.63%) | ||
| KRAS | 0.296 | 0.821 | ||||
| WT | 40 (44.44%) | 82 (52.23%) | 50 (51.02%) | 32 (54.24%) | ||
| Mut | 50 (55.56%) | 75 (47.77%) | 48 (48.98%) | 27 (45.76%) | ||
| BRAF | 0.253 | 1.000 | ||||
| WT | 81 (90.00%) | 149 (94.90%) | 93 (94.90%) | 56 (94.92%) | ||
| V600E mut | 5 (5.56%) | 3 (1.91%) | 2 (2.04%) | 1 (1.69%) | ||
| Other mut | 4 (4.44%) | 5 (3.19%) | 3 (3.06%) | 2 (3.39%) | ||
| MSI/MMR | 0.017 | 0.501 | ||||
| MSI‐H/dMMR | 10 (11.11%) | 4 (2.55%) | 2 (2.04%) | 2 (3.39%) | ||
| MSS/pMMR | 72 (80.00%) | 141 (89.81%) | 90 (91.84%) | 51 (86.44%) | ||
| Unknown | 8 (8.89%) | 12 (7.64%) | 6 (6.12%) | 6 (10.17%) | ||
| Surgery for primary lesion | 0.629 | 0.660 | ||||
| No | 23 (25.56%) | 46 (29.30%) | 27 (27.55%) | 19 (32.20%) | ||
| Yes | 67 (74.44%) | 111 (70.70%) | 71 (72.45%) | 40 (67.80%) | ||
| Targeted therapy | 0.825 | 0.097 | ||||
| No | 38 (42.22%) | 67 (42.68%) | 34 (34.69%) | 33 (55.93%) | ||
| Anti‐VEGF/VEGFR | 26 (28.89%) | 49 (31.21%) | 35 (35.71%) | 14 (23.73%) | ||
| Anti‐EGFR | 8 (8.89%) | 16 (10.19%) | 10 (10.21%) | 6 (10.17%) | ||
| Anti‐VEGF/VEGFR + anti‐EGFR | 7 (7.78%) | 13 (8.28%) | 9 (9.18%) | 4 (6.78%) | ||
| Yes (specific drugs unknown) | 11 (12.22%) | 12 (7.64%) | 10 (10.21%) | 2 (3.39%) | ||
| Chemotherapy | 0.708 | 1.000 | ||||
| No | 3 (3.33%) | 4 (2.55%) | 3 (3.06%) | 1 (1.69%) | ||
| Yes | 87 (96.67%) | 153 (97.45%) | 95 (96.94%) | 58 (98.31%) | ||
Abbreviations: CRC, colorectal cancer; dMMR, deficient mismatch repair; GOF, gain of function; MSI‐H, high microsatellite instability level; MSS, microsatellite stable; pMMR, proficient mismatch repair; WT, wild‐type.